ORKA-001

Phase 2Small molecule

OOruka Therapeutics, Inc.

ORKA-001 is one of 34 small molecule programs targeting Psoriasis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PsoriasisActive, not recruiting

Plaque PsoriasisRecruiting

PsoriasisPhase 2

Active, not recruiting

Plaque PsoriasisPhase 2

Recruiting

Competition

Competitive Landscape

605 competitors in Psoriasis

#DrugCompanyPhaseTrials

Cosentyx

Novartis

Preclinical

53 2

Taltz

Eli Lilly

Preclinical

20 3

Bimzelx

UCB

Preclinical

17 4

Humira

CCelltrion

Preclinical

42 5

Ilumya

Sun Pharmaceutical Industries, Inc.

Preclinical

15 6

Raptiva

Roche

Preclinical

10 7

Remicade

OOrganon and Co

Preclinical

20 8

Siliq

BBausch Health Americas, Inc.

Preclinical

14 9

Victoza

Novo Nordisk

Preclinical

2 10

Lovenox

Sanofi

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Active, not recruiting

Plaque Psoriasis

NCT07090330

Q4 2028

Phase 2Recruiting

Plaque Psoriasis

NCT07290569

Q3 2030

Phase 2Recruiting

Plaque Psoriasis

NCT07449702

Clinical

Trials by Indication[1]

Plaque Psoriasis3 trials

A Multicenter, Randomized, Double-blinded, Placebo-controlled, Dose-range Finding Study of ORKA-001 in Participants With Moderate-to-Severe Plaque Psoriasis

Recruiting·OOruka Therapeutics, Inc.·Phase 2·NCT07290569·160 enrolled

An Open-label Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of ORKA-001 in Participants With Moderate-to-Severe Plaque Psoriasis

Recruiting·OOruka Therapeutics, Inc.·Phase 2·NCT07449702·240 enrolled

A Multicenter, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ORKA-001 in Participants With Moderate-to-Severe Plaque Psoriasis

Active, not recruiting·OOruka Therapeutics, Inc.·Phase 2·NCT07090330·80 enrolled

Unspecified1 trial

ORKA-001 in Healthy Volunteers

Active, not recruiting·OOruka Therapeutics, Inc.·Phase 1·NCT06698939·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for ORKA-001. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ORKA-001 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ORKA-001. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Oruka Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: OOruka Therapeutics, Inc.

ORKA-001

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q4 2028

Q3 2030

Trials by Indication[1]

Plaque Psoriasis3 trials

Unspecified1 trial

References

Drug Info

Quick Facts

Related News